Eszopiclone + placebo

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Fibromyalgia

Conditions

Fibromyalgia, Insomnia

Trial Timeline

Aug 1, 2006 → Mar 1, 2009

NCT ID

NCT00392041

About Eszopiclone + placebo

Eszopiclone + placebo is a approved stage product being developed by Sumitomo Pharma for Fibromyalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00392041. Target conditions include Fibromyalgia, Insomnia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01102270	Phase 1	Completed	Jan 1, 2009	May 1, 2010	Obstructive Sleep Apnea
NCT00645944	Pre-clinical	Completed	Apr 1, 2008	Apr 1, 2011	Insomnia
NCT00826111	Approved	Completed	Aug 1, 2007	Jul 1, 2011	Depression
NCT00414037	Approved	Terminated	Dec 1, 2006	Dec 1, 2008	Primary Insomnia
NCT00386334	Approved	Completed	Oct 1, 2006	Feb 1, 2008	Insomnia
NCT00833547	Pre-clinical	Completed	Sep 1, 2006	Sep 1, 2012	Schizophrenia
NCT00392041	Approved	Completed	Aug 1, 2006	Mar 1, 2009	Fibromyalgia
NCT00365976	Approved	Completed	Aug 1, 2006	Sep 1, 2010	Primary Insomnia
NCT00555750	Pre-clinical	Completed	Mar 1, 2006	Aug 1, 2008	Primary Insomnia
NCT00374192	Pre-clinical	Completed	Feb 1, 2006	Jul 1, 2007	Menopause
NCT00368056	Phase 3	Completed	Apr 1, 2005	Jun 1, 2006	Primary Insomnia
NCT00368160	Phase 1	Completed	Mar 1, 2004	Jul 1, 2005	Insomnia
NCT00367965	Phase 3	Completed	Feb 1, 2004	Nov 1, 2004	Insomnia
NCT00366093	Phase 3	Completed	Feb 1, 2004	Jan 1, 2005	Insomnia
NCT00352144	Phase 3	Completed	Oct 1, 2003	Oct 1, 2004	Primary Insomnia
NCT00685269	Phase 2	Completed	Aug 1, 2003	Jan 1, 2004	Obstructive Sleep Apnea Syndrome

Competing Products

20 competing products in Fibromyalgia

See all competitors

Product	Company	Stage	Hype Score
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	77
DS-5565	Daiichi Sankyo	Phase 3	77
DS-5565 + Placebo	Daiichi Sankyo	Phase 3	77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	77
ASP8062 + Placebo	Astellas Pharma	Phase 2	52
ASP0819 + Placebo	Astellas Pharma	Phase 2	52
Duloxetine	Shionogi	Phase 3	77
Duloxetine 60 mg + Placebo	Shionogi	Phase 3	77
zonisamide	Eisai	Approved	85
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	52
Duloxetine	Eli Lilly	Approved	85
duloxetine hydrochloride + placebo	Eli Lilly	Approved	85
duloxetine	Eli Lilly	Phase 3	77
Duloxetine + placebo	Eli Lilly	Phase 3	77
Duloxetine + Placebo	Eli Lilly	Phase 3	77
Duloxetine + Placebo	Eli Lilly	Approved	85
Treatment for Fibromyalgia	Eli Lilly	Pre-clinical	23
Duloxetine + Placebo	Eli Lilly	Phase 3	77
duloxetine + placebo	Eli Lilly	Phase 3	77

Other Products from Sumitomo Pharma

BlonanserinApproved

Mosapride + domperidoneApproved

levalbuterol HCl + albuterol SulfateApproved

LurasidoneApproved

placebo, isotonic ciclesonide, hypotonic ciclesonideApproved